Skip to main content
VKTX
NASDAQ Life Sciences

Roche's Enicepatide Hits Phase 2 Goals in Diabetes-Obesity, Intensifying GLP-1 Race

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$38.133
Mkt Cap
$4.448B
52W Low
$24.52
52W High
$43.15
52W Position info
56% above low
Off High info
12% below high
Rel. Volume info
10× avg
Market data snapshot near publication time

VKTX sits 56% above its 52-week low of $24.52 on elevated volume (10× avg).

Summary

Roche's enicepatide met Phase 2 endpoints in Type 2 diabetes with obesity, showing 2.65 percentage point HbA1c reduction and 15.5% weight loss at 48 weeks. This directly challenges Viking's VK2735, which reported positive maintenance data the same day. Roche plans a late-stage cardiovascular outcomes program in H1 2027, signaling deep commitment to the obesity market. For Viking, a well-capitalized competitor with strong data raises the bar for differentiation and partnership appeal. Watch for Viking's Phase 3 VANQUISH readouts and any partnership announcements as competitive pressure mounts.

At the time of this announcement, VKTX was trading at $38.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $24.52 to $43.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

VKTX - Latest Insights

VKTX
Oct 29, 2026, 10:43 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $27.18
Real-time Price: $24.88 info
Change: -$2.30 (-8%) info
Market Cap: $3.173B info
VKTX
Oct 28, 2026, 5:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.70
Real-time Price: $24.88 info
Change: +$0.1746 (+0.71%) info
Market Cap: $3.173B info
VKTX
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.38
Real-time Price: $24.88 info
Change: +$0.495 (+2%) info
Market Cap: $3.173B info
VKTX
Oct 28, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.41
Real-time Price: $24.88 info
Change: -$0.535 (-2%) info
Market Cap: $3.173B info
VKTX
Sep 28, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.28
Real-time Price: $24.88 info
Change: -$8.41 (-25%) info
Market Cap: $3.173B info